Novo Nordisk (NVO) profits Q2 2025

sales Novo NordskThe company said in its latest report, as it pledged to reduce costs after the shares loss.

Wegovy Obsity DROG revenues increased by 67 % to 19.53 billion kroner in the three months until the end of June, slightly less than the 20 billion Danish Crohn expectations.

The shares decreased by 1.2 % by 10:07 am London time (5:07 am EST).

Total sales increased by 13 % on an annual basis at fixed exchange rates to 76.86 billion Danish Kron (11.92 billion dollars) during this period, before the Danish Kroner analyst expected 76.6 billion.

The net separation profit reached 26.5 billion Danish Crohn, compared to 26.6 billion kronor.

The Danish drug maker repeated his outlook throughout the year after its guidelines were reduced last week on the expectations of sales growth in the second weakened half for Wegovy and the treatment of Azini diabetes.

The company now expects 8 % annual sales growth to 14 % in fixed exchange rates, as well as annual operating profit growth from 10 % to 16 %.

Novo Nordisk also said it would reduce costs and cook its commercial focus after receiving the company’s share price over the announcement of last week, which extends to long declines since its peak in June 2024.

“We are taking measures to increase our commercial implementation, and ensure efficiency in our cost base, while continuing to invest in future growth,” said the president and CEO of CEO of Ers Ferrogard Jurgenin in a statement accompanying the results.

Last week, he said the role is “a feeling of urgency, the concentration of the laser on high performance, and a fierce design on Novo Nordisk for the goal is higher than ever.”

The sudden overthrow of the Fruergaard jditionsen was overthrown in May where the company was fighting the most softened US sales amid an increasing competition from complex drug makers and main competition. Disappointed experimental results For the next generation of obesity, CAGRISEMA, added to the company’s problems.

The broader pharmaceutical industry is facing the possibility of a major tariff in the White House – which was said by US President Donald Trump on Tuesday. Run up to 250 % – The pressure from the administration to the low prices of local drugs.

The White House said on Thursday that President Trump had it Messages sent To 17 major pharmaceutical companies, including Novo Nordisk, the steps you must take to reduce the price of medicines prescribed in the United States to the levels of the “most preferred nation” (MFN) by September 29.